The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilar and Biologics Market Research Report 2025
Synopsis
The global Biosimilar and Biologics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Biosimilar and Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Biosimilar and Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Biosimilar and Biologics include Pfizer, Roche AG, AbbVie, Novartis AG, Merck, Bristol Myers Squibb, GSK, AstraZeneca and Eli Lilly, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Biosimilar and Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar and Biologics.
Report Scope
The Biosimilar and Biologics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar and Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar and Biologics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Roche AG
AbbVie
Novartis AG
Merck
Bristol Myers Squibb
GSK
AstraZeneca
Eli Lilly
Bayer
Gilead Sciences
Amgen
Boehringer Ingelheim
Novo Nordisk
Viatris
Johnson
Sanofi Winthrop Industries
Serum Institute of India
Biocon
Intas Pharmaceuticals
Segment by Type
Monoclonal Antibody
Vaccines
Recombinant Insulin
Growth Factors
Immune Modulators
Fusion Protein
Erythoprotein
Other
Segment by Application
Autoimmune Diseases
Infectious Diseases
Cardiovascular Disorders
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar and Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar and Biologics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Biosimilar and Biologics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Biosimilar and Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Biosimilar and Biologics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Biosimilar and Biologics include Pfizer, Roche AG, AbbVie, Novartis AG, Merck, Bristol Myers Squibb, GSK, AstraZeneca and Eli Lilly, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Biosimilar and Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar and Biologics.
Report Scope
The Biosimilar and Biologics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar and Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar and Biologics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Roche AG
AbbVie
Novartis AG
Merck
Bristol Myers Squibb
GSK
AstraZeneca
Eli Lilly
Bayer
Gilead Sciences
Amgen
Boehringer Ingelheim
Novo Nordisk
Viatris
Johnson
Sanofi Winthrop Industries
Serum Institute of India
Biocon
Intas Pharmaceuticals
Segment by Type
Monoclonal Antibody
Vaccines
Recombinant Insulin
Growth Factors
Immune Modulators
Fusion Protein
Erythoprotein
Other
Segment by Application
Autoimmune Diseases
Infectious Diseases
Cardiovascular Disorders
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Biosimilar and Biologics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Biosimilar and Biologics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Biosimilar and Biologics Market Overview
1.1 Product Overview and Scope of Biosimilar and Biologics
1.2 Biosimilar and Biologics Segment by Type
1.2.1 Global Biosimilar and Biologics Market Value Comparison by Type (2024-2030)
1.2.2 Monoclonal Antibody
1.2.3 Vaccines
1.2.4 Recombinant Insulin
1.2.5 Growth Factors
1.2.6 Immune Modulators
1.2.7 Fusion Protein
1.2.8 Erythoprotein
1.2.9 Other
1.3 Biosimilar and Biologics Segment by Application
1.3.1 Global Biosimilar and Biologics Market Value by Application: (2024-2030)
1.3.2 Autoimmune Diseases
1.3.3 Infectious Diseases
1.3.4 Cardiovascular Disorders
1.3.5 Other
1.4 Global Biosimilar and Biologics Market Size Estimates and Forecasts
1.4.1 Global Biosimilar and Biologics Revenue 2019-2030
1.4.2 Global Biosimilar and Biologics Sales 2019-2030
1.4.3 Global Biosimilar and Biologics Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Biosimilar and Biologics Market Competition by Manufacturers
2.1 Global Biosimilar and Biologics Sales Market Share by Manufacturers (2019-2024)
2.2 Global Biosimilar and Biologics Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Biosimilar and Biologics Average Price by Manufacturers (2019-2024)
2.4 Global Biosimilar and Biologics Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilar and Biologics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilar and Biologics, Product Type & Application
2.7 Biosimilar and Biologics Market Competitive Situation and Trends
2.7.1 Biosimilar and Biologics Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilar and Biologics Players Market Share by Revenue
2.7.3 Global Biosimilar and Biologics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilar and Biologics Retrospective Market Scenario by Region
3.1 Global Biosimilar and Biologics Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Biosimilar and Biologics Global Biosimilar and Biologics Sales by Region: 2019-2030
3.2.1 Global Biosimilar and Biologics Sales by Region: 2019-2024
3.2.2 Global Biosimilar and Biologics Sales by Region: 2025-2030
3.3 Global Biosimilar and Biologics Global Biosimilar and Biologics Revenue by Region: 2019-2030
3.3.1 Global Biosimilar and Biologics Revenue by Region: 2019-2024
3.3.2 Global Biosimilar and Biologics Revenue by Region: 2025-2030
3.4 North America Biosimilar and Biologics Market Facts & Figures by Country
3.4.1 North America Biosimilar and Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Biosimilar and Biologics Sales by Country (2019-2030)
3.4.3 North America Biosimilar and Biologics Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biosimilar and Biologics Market Facts & Figures by Country
3.5.1 Europe Biosimilar and Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Biosimilar and Biologics Sales by Country (2019-2030)
3.5.3 Europe Biosimilar and Biologics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilar and Biologics Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilar and Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Biosimilar and Biologics Sales by Country (2019-2030)
3.6.3 Asia Pacific Biosimilar and Biologics Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Biosimilar and Biologics Market Facts & Figures by Country
3.7.1 Latin America Biosimilar and Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Biosimilar and Biologics Sales by Country (2019-2030)
3.7.3 Latin America Biosimilar and Biologics Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilar and Biologics Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilar and Biologics Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Biosimilar and Biologics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Biosimilar and Biologics Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilar and Biologics Sales by Type (2019-2030)
4.1.1 Global Biosimilar and Biologics Sales by Type (2019-2024)
4.1.2 Global Biosimilar and Biologics Sales by Type (2025-2030)
4.1.3 Global Biosimilar and Biologics Sales Market Share by Type (2019-2030)
4.2 Global Biosimilar and Biologics Revenue by Type (2019-2030)
4.2.1 Global Biosimilar and Biologics Revenue by Type (2019-2024)
4.2.2 Global Biosimilar and Biologics Revenue by Type (2025-2030)
4.2.3 Global Biosimilar and Biologics Revenue Market Share by Type (2019-2030)
4.3 Global Biosimilar and Biologics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Biosimilar and Biologics Sales by Application (2019-2030)
5.1.1 Global Biosimilar and Biologics Sales by Application (2019-2024)
5.1.2 Global Biosimilar and Biologics Sales by Application (2025-2030)
5.1.3 Global Biosimilar and Biologics Sales Market Share by Application (2019-2030)
5.2 Global Biosimilar and Biologics Revenue by Application (2019-2030)
5.2.1 Global Biosimilar and Biologics Revenue by Application (2019-2024)
5.2.2 Global Biosimilar and Biologics Revenue by Application (2025-2030)
5.2.3 Global Biosimilar and Biologics Revenue Market Share by Application (2019-2030)
5.3 Global Biosimilar and Biologics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Biosimilar and Biologics Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Roche AG
6.2.1 Roche AG Corporation Information
6.2.2 Roche AG Description and Business Overview
6.2.3 Roche AG Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Roche AG Biosimilar and Biologics Product Portfolio
6.2.5 Roche AG Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Corporation Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AbbVie Biosimilar and Biologics Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 Novartis AG
6.4.1 Novartis AG Corporation Information
6.4.2 Novartis AG Description and Business Overview
6.4.3 Novartis AG Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis AG Biosimilar and Biologics Product Portfolio
6.4.5 Novartis AG Recent Developments/Updates
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Merck Biosimilar and Biologics Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Bristol Myers Squibb
6.6.1 Bristol Myers Squibb Corporation Information
6.6.2 Bristol Myers Squibb Description and Business Overview
6.6.3 Bristol Myers Squibb Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bristol Myers Squibb Biosimilar and Biologics Product Portfolio
6.6.5 Bristol Myers Squibb Recent Developments/Updates
6.7 GSK
6.6.1 GSK Corporation Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GSK Biosimilar and Biologics Product Portfolio
6.7.5 GSK Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Corporation Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 AstraZeneca Biosimilar and Biologics Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 Eli Lilly
6.9.1 Eli Lilly Corporation Information
6.9.2 Eli Lilly Description and Business Overview
6.9.3 Eli Lilly Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Eli Lilly Biosimilar and Biologics Product Portfolio
6.9.5 Eli Lilly Recent Developments/Updates
6.10 Bayer
6.10.1 Bayer Corporation Information
6.10.2 Bayer Description and Business Overview
6.10.3 Bayer Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Bayer Biosimilar and Biologics Product Portfolio
6.10.5 Bayer Recent Developments/Updates
6.11 Gilead Sciences
6.11.1 Gilead Sciences Corporation Information
6.11.2 Gilead Sciences Biosimilar and Biologics Description and Business Overview
6.11.3 Gilead Sciences Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Gilead Sciences Biosimilar and Biologics Product Portfolio
6.11.5 Gilead Sciences Recent Developments/Updates
6.12 Amgen
6.12.1 Amgen Corporation Information
6.12.2 Amgen Biosimilar and Biologics Description and Business Overview
6.12.3 Amgen Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Amgen Biosimilar and Biologics Product Portfolio
6.12.5 Amgen Recent Developments/Updates
6.13 Boehringer Ingelheim
6.13.1 Boehringer Ingelheim Corporation Information
6.13.2 Boehringer Ingelheim Biosimilar and Biologics Description and Business Overview
6.13.3 Boehringer Ingelheim Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Boehringer Ingelheim Biosimilar and Biologics Product Portfolio
6.13.5 Boehringer Ingelheim Recent Developments/Updates
6.14 Novo Nordisk
6.14.1 Novo Nordisk Corporation Information
6.14.2 Novo Nordisk Biosimilar and Biologics Description and Business Overview
6.14.3 Novo Nordisk Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Novo Nordisk Biosimilar and Biologics Product Portfolio
6.14.5 Novo Nordisk Recent Developments/Updates
6.15 Viatris
6.15.1 Viatris Corporation Information
6.15.2 Viatris Biosimilar and Biologics Description and Business Overview
6.15.3 Viatris Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Viatris Biosimilar and Biologics Product Portfolio
6.15.5 Viatris Recent Developments/Updates
6.16 Johnson
6.16.1 Johnson Corporation Information
6.16.2 Johnson Biosimilar and Biologics Description and Business Overview
6.16.3 Johnson Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Johnson Biosimilar and Biologics Product Portfolio
6.16.5 Johnson Recent Developments/Updates
6.17 Sanofi Winthrop Industries
6.17.1 Sanofi Winthrop Industries Corporation Information
6.17.2 Sanofi Winthrop Industries Biosimilar and Biologics Description and Business Overview
6.17.3 Sanofi Winthrop Industries Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Sanofi Winthrop Industries Biosimilar and Biologics Product Portfolio
6.17.5 Sanofi Winthrop Industries Recent Developments/Updates
6.18 Serum Institute of India
6.18.1 Serum Institute of India Corporation Information
6.18.2 Serum Institute of India Biosimilar and Biologics Description and Business Overview
6.18.3 Serum Institute of India Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Serum Institute of India Biosimilar and Biologics Product Portfolio
6.18.5 Serum Institute of India Recent Developments/Updates
6.19 Biocon
6.19.1 Biocon Corporation Information
6.19.2 Biocon Biosimilar and Biologics Description and Business Overview
6.19.3 Biocon Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Biocon Biosimilar and Biologics Product Portfolio
6.19.5 Biocon Recent Developments/Updates
6.20 Intas Pharmaceuticals
6.20.1 Intas Pharmaceuticals Corporation Information
6.20.2 Intas Pharmaceuticals Biosimilar and Biologics Description and Business Overview
6.20.3 Intas Pharmaceuticals Biosimilar and Biologics Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Intas Pharmaceuticals Biosimilar and Biologics Product Portfolio
6.20.5 Intas Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilar and Biologics Industry Chain Analysis
7.2 Biosimilar and Biologics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilar and Biologics Production Mode & Process
7.4 Biosimilar and Biologics Sales and Marketing
7.4.1 Biosimilar and Biologics Sales Channels
7.4.2 Biosimilar and Biologics Distributors
7.5 Biosimilar and Biologics Customers
8 Biosimilar and Biologics Market Dynamics
8.1 Biosimilar and Biologics Industry Trends
8.2 Biosimilar and Biologics Market Drivers
8.3 Biosimilar and Biologics Market Challenges
8.4 Biosimilar and Biologics Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Biosimilar and Biologics Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Biosimilar and Biologics Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Biosimilar and Biologics Market Competitive Situation by Manufacturers in 2023
Table 4. Global Biosimilar and Biologics Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Biosimilar and Biologics Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Biosimilar and Biologics Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Biosimilar and Biologics Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Biosimilar and Biologics Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Biosimilar and Biologics, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Biosimilar and Biologics, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Biosimilar and Biologics, Product Type & Application
Table 12. Global Key Manufacturers of Biosimilar and Biologics, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilar and Biologics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar and Biologics as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biosimilar and Biologics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Biosimilar and Biologics Sales by Region (2019-2024) & (K Units)
Table 18. Global Biosimilar and Biologics Sales Market Share by Region (2019-2024)
Table 19. Global Biosimilar and Biologics Sales by Region (2025-2030) & (K Units)
Table 20. Global Biosimilar and Biologics Sales Market Share by Region (2025-2030)
Table 21. Global Biosimilar and Biologics Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Biosimilar and Biologics Revenue Market Share by Region (2019-2024)
Table 23. Global Biosimilar and Biologics Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Biosimilar and Biologics Revenue Market Share by Region (2025-2030)
Table 25. North America Biosimilar and Biologics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Biosimilar and Biologics Sales by Country (2019-2024) & (K Units)
Table 27. North America Biosimilar and Biologics Sales by Country (2025-2030) & (K Units)
Table 28. North America Biosimilar and Biologics Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Biosimilar and Biologics Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Biosimilar and Biologics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Biosimilar and Biologics Sales by Country (2019-2024) & (K Units)
Table 32. Europe Biosimilar and Biologics Sales by Country (2025-2030) & (K Units)
Table 33. Europe Biosimilar and Biologics Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Biosimilar and Biologics Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Biosimilar and Biologics Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Biosimilar and Biologics Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Biosimilar and Biologics Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Biosimilar and Biologics Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Biosimilar and Biologics Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Biosimilar and Biologics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Biosimilar and Biologics Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Biosimilar and Biologics Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Biosimilar and Biologics Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Biosimilar and Biologics Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Biosimilar and Biologics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Biosimilar and Biologics Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Biosimilar and Biologics Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Biosimilar and Biologics Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Biosimilar and Biologics Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Biosimilar and Biologics Sales (K Units) by Type (2019-2024)
Table 51. Global Biosimilar and Biologics Sales (K Units) by Type (2025-2030)
Table 52. Global Biosimilar and Biologics Sales Market Share by Type (2019-2024)
Table 53. Global Biosimilar and Biologics Sales Market Share by Type (2025-2030)
Table 54. Global Biosimilar and Biologics Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Biosimilar and Biologics Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Biosimilar and Biologics Revenue Market Share by Type (2019-2024)
Table 57. Global Biosimilar and Biologics Revenue Market Share by Type (2025-2030)
Table 58. Global Biosimilar and Biologics Price (US$/Unit) by Type (2019-2024)
Table 59. Global Biosimilar and Biologics Price (US$/Unit) by Type (2025-2030)
Table 60. Global Biosimilar and Biologics Sales (K Units) by Application (2019-2024)
Table 61. Global Biosimilar and Biologics Sales (K Units) by Application (2025-2030)
Table 62. Global Biosimilar and Biologics Sales Market Share by Application (2019-2024)
Table 63. Global Biosimilar and Biologics Sales Market Share by Application (2025-2030)
Table 64. Global Biosimilar and Biologics Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Biosimilar and Biologics Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Biosimilar and Biologics Revenue Market Share by Application (2019-2024)
Table 67. Global Biosimilar and Biologics Revenue Market Share by Application (2025-2030)
Table 68. Global Biosimilar and Biologics Price (US$/Unit) by Application (2019-2024)
Table 69. Global Biosimilar and Biologics Price (US$/Unit) by Application (2025-2030)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Pfizer Biosimilar and Biologics Product
Table 74. Pfizer Recent Developments/Updates
Table 75. Roche AG Corporation Information
Table 76. Roche AG Description and Business Overview
Table 77. Roche AG Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Roche AG Biosimilar and Biologics Product
Table 79. Roche AG Recent Developments/Updates
Table 80. AbbVie Corporation Information
Table 81. AbbVie Description and Business Overview
Table 82. AbbVie Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. AbbVie Biosimilar and Biologics Product
Table 84. AbbVie Recent Developments/Updates
Table 85. Novartis AG Corporation Information
Table 86. Novartis AG Description and Business Overview
Table 87. Novartis AG Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Novartis AG Biosimilar and Biologics Product
Table 89. Novartis AG Recent Developments/Updates
Table 90. Merck Corporation Information
Table 91. Merck Description and Business Overview
Table 92. Merck Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Merck Biosimilar and Biologics Product
Table 94. Merck Recent Developments/Updates
Table 95. Bristol Myers Squibb Corporation Information
Table 96. Bristol Myers Squibb Description and Business Overview
Table 97. Bristol Myers Squibb Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Bristol Myers Squibb Biosimilar and Biologics Product
Table 99. Bristol Myers Squibb Recent Developments/Updates
Table 100. GSK Corporation Information
Table 101. GSK Description and Business Overview
Table 102. GSK Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. GSK Biosimilar and Biologics Product
Table 104. GSK Recent Developments/Updates
Table 105. AstraZeneca Corporation Information
Table 106. AstraZeneca Description and Business Overview
Table 107. AstraZeneca Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. AstraZeneca Biosimilar and Biologics Product
Table 109. AstraZeneca Recent Developments/Updates
Table 110. Eli Lilly Corporation Information
Table 111. Eli Lilly Description and Business Overview
Table 112. Eli Lilly Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Eli Lilly Biosimilar and Biologics Product
Table 114. Eli Lilly Recent Developments/Updates
Table 115. Bayer Corporation Information
Table 116. Bayer Description and Business Overview
Table 117. Bayer Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Bayer Biosimilar and Biologics Product
Table 119. Bayer Recent Developments/Updates
Table 120. Gilead Sciences Corporation Information
Table 121. Gilead Sciences Description and Business Overview
Table 122. Gilead Sciences Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Gilead Sciences Biosimilar and Biologics Product
Table 124. Gilead Sciences Recent Developments/Updates
Table 125. Amgen Corporation Information
Table 126. Amgen Description and Business Overview
Table 127. Amgen Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Amgen Biosimilar and Biologics Product
Table 129. Amgen Recent Developments/Updates
Table 130. Boehringer Ingelheim Corporation Information
Table 131. Boehringer Ingelheim Description and Business Overview
Table 132. Boehringer Ingelheim Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Boehringer Ingelheim Biosimilar and Biologics Product
Table 134. Boehringer Ingelheim Recent Developments/Updates
Table 135. Novo Nordisk Corporation Information
Table 136. Novo Nordisk Description and Business Overview
Table 137. Novo Nordisk Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Novo Nordisk Biosimilar and Biologics Product
Table 139. Novo Nordisk Recent Developments/Updates
Table 140. Viatris Corporation Information
Table 141. Viatris Description and Business Overview
Table 142. Viatris Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Viatris Biosimilar and Biologics Product
Table 144. Viatris Recent Developments/Updates
Table 145. Johnson Corporation Information
Table 146. Johnson Description and Business Overview
Table 147. Johnson Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Johnson Biosimilar and Biologics Product
Table 149. Johnson Recent Developments/Updates
Table 150. Sanofi Winthrop Industries Corporation Information
Table 151. Sanofi Winthrop Industries Description and Business Overview
Table 152. Sanofi Winthrop Industries Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Sanofi Winthrop Industries Biosimilar and Biologics Product
Table 154. Sanofi Winthrop Industries Recent Developments/Updates
Table 155. Serum Institute of India Corporation Information
Table 156. Serum Institute of India Description and Business Overview
Table 157. Serum Institute of India Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 158. Serum Institute of India Biosimilar and Biologics Product
Table 159. Serum Institute of India Recent Developments/Updates
Table 160. Biocon Corporation Information
Table 161. Biocon Description and Business Overview
Table 162. Biocon Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 163. Biocon Biosimilar and Biologics Product
Table 164. Biocon Recent Developments/Updates
Table 165. Intas Pharmaceuticals Corporation Information
Table 166. Intas Pharmaceuticals Description and Business Overview
Table 167. Intas Pharmaceuticals Biosimilar and Biologics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 168. Intas Pharmaceuticals Biosimilar and Biologics Product
Table 169. Intas Pharmaceuticals Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Biosimilar and Biologics Distributors List
Table 173. Biosimilar and Biologics Customers List
Table 174. Biosimilar and Biologics Market Trends
Table 175. Biosimilar and Biologics Market Drivers
Table 176. Biosimilar and Biologics Market Challenges
Table 177. Biosimilar and Biologics Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biosimilar and Biologics
Figure 2. Global Biosimilar and Biologics Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Biosimilar and Biologics Market Share by Type in 2023 & 2030
Figure 4. Monoclonal Antibody Product Picture
Figure 5. Vaccines Product Picture
Figure 6. Recombinant Insulin Product Picture
Figure 7. Growth Factors Product Picture
Figure 8. Immune Modulators Product Picture
Figure 9. Fusion Protein Product Picture
Figure 10. Erythoprotein Product Picture
Figure 11. Other Product Picture
Figure 12. Global Biosimilar and Biologics Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 13. Global Biosimilar and Biologics Market Share by Application in 2023 & 2030
Figure 14. Autoimmune Diseases
Figure 15. Infectious Diseases
Figure 16. Cardiovascular Disorders
Figure 17. Other
Figure 18. Global Biosimilar and Biologics Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 19. Global Biosimilar and Biologics Market Size (2019-2030) & (US$ Million)
Figure 20. Global Biosimilar and Biologics Sales (2019-2030) & (K Units)
Figure 21. Global Biosimilar and Biologics Average Price (US$/Unit) & (2019-2030)
Figure 22. Biosimilar and Biologics Report Years Considered
Figure 23. Biosimilar and Biologics Sales Share by Manufacturers in 2023
Figure 24. Global Biosimilar and Biologics Revenue Share by Manufacturers in 2023
Figure 25. The Global 5 and 10 Largest Biosimilar and Biologics Players: Market Share by Revenue in 2023
Figure 26. Biosimilar and Biologics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 27. Global Biosimilar and Biologics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 28. North America Biosimilar and Biologics Sales Market Share by Country (2019-2030)
Figure 29. North America Biosimilar and Biologics Revenue Market Share by Country (2019-2030)
Figure 30. United States Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Canada Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Europe Biosimilar and Biologics Sales Market Share by Country (2019-2030)
Figure 33. Europe Biosimilar and Biologics Revenue Market Share by Country (2019-2030)
Figure 34. Germany Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. France Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. U.K. Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Italy Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Russia Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Asia Pacific Biosimilar and Biologics Sales Market Share by Region (2019-2030)
Figure 40. Asia Pacific Biosimilar and Biologics Revenue Market Share by Region (2019-2030)
Figure 41. China Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Japan Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. South Korea Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. India Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Australia Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. China Taiwan Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America Biosimilar and Biologics Sales Market Share by Country (2019-2030)
Figure 49. Latin America Biosimilar and Biologics Revenue Market Share by Country (2019-2030)
Figure 50. Mexico Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Brazil Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Argentina Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Middle East & Africa Biosimilar and Biologics Sales Market Share by Country (2019-2030)
Figure 54. Middle East & Africa Biosimilar and Biologics Revenue Market Share by Country (2019-2030)
Figure 55. Turkey Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. UAE Biosimilar and Biologics Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Global Sales Market Share of Biosimilar and Biologics by Type (2019-2030)
Figure 59. Global Revenue Market Share of Biosimilar and Biologics by Type (2019-2030)
Figure 60. Global Biosimilar and Biologics Price (US$/Unit) by Type (2019-2030)
Figure 61. Global Sales Market Share of Biosimilar and Biologics by Application (2019-2030)
Figure 62. Global Revenue Market Share of Biosimilar and Biologics by Application (2019-2030)
Figure 63. Global Biosimilar and Biologics Price (US$/Unit) by Application (2019-2030)
Figure 64. Biosimilar and Biologics Value Chain
Figure 65. Biosimilar and Biologics Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
